TGFBR2

Across TCGA pan-cancer cohorts, TGFBR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TGFBR2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TGFBR2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TGFBR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and PAAD are the cancer types where TGFBR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.205	0.668	<.001	39	view →
UCEC	DFS	Median	All	0.964	0.620	.017	28	view →
PAAD	OS	Median	All	0.142	0.645	<.001	12	view →
SKCM	OS	Median	III,IV	0.597	0.845	.011	7	view →
ESCA	OS	Median	III,IV	0.117	0.563	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TGFBR2–LUSC (DFS)

Open the LUSC breakdown →